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Abstract 
Background 
Randomized controlled trials are the sine qua non of causal inference; however, heterogeneity 
of treatment effects for many chronic conditions and for many symptoms often limits their 
utility. Single-patient studies in which patients select a treatment after trying a randomized 
sequence of treatments (i.e., multiple crossover trials) offer an alternative to traditional 
randomized controlled trials by providing scientifically valid results in a practical manner that 
can be used by patients and their providers to decide upon their personally optimal treatment. 
Although N-of-1 trials have been used in the medical literature, their use for interventions 
that consist of psychological or health behavior outcomes is unknown. This systematic 
review thus aims to describe the interventions and outcomes and assess the quality of N-of-1 
trials for psychological or health behavior outcomes.  
Methods/design 
Electronic databases (Ovid MEDLINE, EMBASE, CINAHL, PsycINFO, and the six 
databases in the Cochrane Library) will be searched using all relevant subject headings and 
free-text terms to represent N-of-1 trials and psychological or behavioral interventions. Full 
text review and bibliography searching will be conducted. Unpublished studies will be sought 
by searching trial registries and contacting authors of included studies. Eligibility criteria are 
the following: population, all human participants for whom N-of-1 trials with psychological 
or health behavior outcomes have been conducted; interventions, all interventions for which 
N-of-1 trials have been conducted; comparison, placebo or active treatment control; and 
outcome, psychological and health behavior outcomes including self-perceived disease 
severity and psychological phenomena such as mood and affect. Studies that do not contain 
sufficient trial detail, describe only design or statistical analytic issues in N-of-1 trials without 
presentation of an N-of-1 trial itself, and/or are not written in the English language are 
ineligible. Screening, data extraction, and quality assessment will be conducted by two 
independent reviewers with disagreements resolved through discussion.  
Discussion 
This systematic review will describe the interventions and outcomes and  assess the quality of 
N-of-1 trials for psychological or health behavior outcomes. The results will clarify the use of 
this research methodology in the health psychology and behavioral medicine literature and 
may pave the way for additional N-of-1 trials to be conducted. 
Systematic review registration 
PROSPERO CRD42015017853 
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Background 
Despite their commonly lauded role as the gold standard of causal inference and the 
cornerstone of evidence-based medicine, randomized controlled trials (RCT) often fail to 
provide evidence for individualized therapeutic decisions. Indeed, heterogeneity of treatment 
effects (HTE) is evident for many RCTs for many chronic conditions and for many 
symptoms, such that some RCT-supported treatments can have huge benefits for some 
patients but can be minimally effective or even harmful for others [1, 2]. Further, traditional, 
two-arm, parallel group RCTs can be costly to conduct, leaving clinicians and researchers to 
rely on clinical experience rather than strong experimental evidence [3]. As these 
conventional RCTs provide only the average treatment effect of an intervention for a group of 
patients, patients and clinicians need additional information about the effect of a specific 
treatment for a specific patient for a specific problem [2].  
The Evidence-Based Medicine Working Group suggested that N-of-1 trials “provide the 
strongest evidence for the decisions of patients [4].” N-of-1 trials are single-patient studies in 
which patients select a treatment after trying a series of treatments (i.e., multiple crossover 
trials) to determine the relative benefits and harms of each treatment for themselves [1]. They 
focus on the individual patient by randomizing comparative treatments across time within 
each patient, rather than randomizing different patients to different comparative treatments as 
is done in a traditional RCT. Thus, instead of using the results of a conventional or between-
patient RCT to choose the best treatment for a patient, the N-of-1 trial methodology can 
provide scientifically valid results and therefore valuable information in a practical manner 
that can be used by patients and providers to decide upon a personally optimal treatment and 
so overcome HTE. In this way, N-of-1 trials are the foundational design for a truly patient-
centered comparative effectiveness method. Further, N-of-1 trials are specifically designed to 
help patients make healthcare decisions that are informed by high- integrity, evidence-based 
information that is uniquely relevant to their important outcomes and values [5]. In a series of 
demonstration trials, N-of-1 designs have led to valuable changes in treatment, cessation of 
treatment, or confirmation of the original treatment [6–10]. For example, in one series of 71 
N-of-1 trials for patients with either chronic pain or osteoarthritis, 46 patients (65 %) decided 
to change their pain medication as a result of the information from the trials, and of the 37 
patients using an NSAID or Cox-2 inhibitor drug for pain management before their trials, 12 
(32 %) decided that the medication was not helping and stopped it, as a result of their trial 
results. 
Notwithstanding the proliferation of N-of-1 trials in the medical literature, randomized N-of-
1 trials have only sporadically been used for treatments that target psychological or health 
behavior outcomes. Furthermore, among those N-of-1 studies that have considered 
psychological or health behavior outcomes, information regarding study quality and methods 
for assessing study quality is limited. This gap in knowledge is peculiar given the abundance 
of other single participant study designs (e.g., ABA designs, multiple baseline designs, and 
time-series designs) in the psychology literature and the push to tailor psychological 
interventions to the individuality of the patient and the singularity of his or her context and 
condition [11]. It is with these gaps in knowledge in mind that we endeavored to conduct a 




The proposed review aims to describe the interventions and outcomes and assess the quality 
of N-of-1 trials for psychological or health behavior outcomes. The reporting of this review 
will conform to Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guidelines [12]. 
Eligibility criteria 
Population: This review is not limited to a particular population, but will consider all 
populations for whom N-of-1 trials have been conducted. 
Interventions: All medical, psychological, and behavioral interventions for which N-of-1 
trials have been conducted (i.e., no restrictions on interventions) will be considered.  
Comparator/control: Inclusion criteria require placebo control or an active treatment control.  
Outcomes: Psychological and health behavior outcomes will be considered in the following 
categories: 
1. Behavioral—defined as a response that can be conditioned and is objectively observable 
(e.g., number of steps). 
2. Self-perceived disease severity or disease processes—defined as patient ratings of disease 
severity or disease processes, including but not limited to pain, dyspnea, and 
gastrointestinal discomfort.  
3. Psychological—defined as self-reported affective functioning, including but not limited to 
depression and anxiety. 
Study design 
Only peer-reviewed studies in full text, conference abstract, or doctoral dissertations are 
eligible for this review. Studies must involve randomization of treatments within blocks or 
pairs, crossover of interventions, individual patients or series of patients, and single patients 
as the unit of analysis. 
Exclusion 
Studies that do not contain sufficient trial detail, consist primarily of methods and review 
(e.g., Lillie and colleagues [13] discuss design issues and the analysis of N-of-1 trials but do 
not report an N-of-1 trial of their own), and/or are not written in English will be ineligible as 
these will make assessment of study quality impossible.  
Search strategy 
Potentially relevant articles will be identified by searching the biomedical electronic 
databases Ovid MEDLINE, EMBASE, all six databases in The Cochrane Library, CINAHL, 
and PsycINFO. All relevant subject headings and free-text terms will be used to represent N-
of-1 controlled trials and psychological or behavioral interventions, and databases will be 
searched from inception through the week of planned manuscript submission. Terms for 
MEDLINE will include the following: n-of-1.tw OR ((individual or single) adj (patient$ or 
participant$ or subject$)).tw. OR ipd.tw AND exp Behavioral Medicine/ OR exp 
psychotherapy/ OR behavio$ adj (change or health or medicine or therap$)).tw OR 
psychotherap$.tw. OR psycholog$.tw. (see Additional file 1: for full strategies). These terms 
will be adapted for the other databases. Ongoing studies will also be sought through 
Clinicaltrials.gov and the WHO International Clinical Trials Registry Platform. Additional 
records will be identified by scanning the reference lists of relevant studies and reviews, by 
employing the Related Articles feature in PubMed, and by using the Cited Reference Search 
in Scopus. 
Search selection process 
Two reviewers (JAS, LF) will independently screen titles and abstracts of all the retrieved 
bibliographic records. Full texts of potentially eligible records passing the title and abstract 
screening level will be retrieved and examined independently by the two reviewers according 
to the above mentioned eligibility criteria. Disagreements at both screening levels 
(title/abstract and full text) will be adjudicated by a third reviewer (KWD). A PRISMA flow 
chart will outline the study selection process and reasons for exclusions.  
Assessment of study quality 
Assessment of study quality will be performed by two reviewers (JAS, LF) according to the 
Consolidated Standards of Reporting Trials (CONSORT) statement [14] and the CONSORT 
extension for N-of-1 Trials (CENT) (Table 1) [15]. After determination of a study’s 
eligibility, the following information will be reviewed and determined to be either reported or 
not reported: introduction (scientific background and explanation of rationale, specific 
objectives or hypotheses, rationale for using an N-of-1 approach), trial design characteristics 
(description of trial design with planned number of periods and duration of each period, 
individualization of the design for series of participants, important changes to methods after 
trial commencement, participant eligibility criteria, duration of treatment periods), 
intervention and outcome characteristics with sufficient detail to allow replication 
(completely defined primary and secondary endpoints, measurement properties of outcome 
assessment tools, changes to trial outcomes), allocation characteristics (allocation method, 
blinding, allocation concealment mechanism, allocation implementation), statistical analytic 
methods (sample size determination, explanation of interim analyses and stopping guidelines, 
consideration of carry-over effects, period effects, intra-participant associations, and methods 
of quantitative synthesis of series data), results (number and sequence of periods completed, 
number of participants enrolled and assigned to intervention, losses or exclusion of 
participations after treatment assignment, table showing baseline data, number of periods 
analyzed, number of trials for which data were synthesized, results for each primary and 
secondary endpoint per period, estimated effect size and precision, results of any additional 
analyses), harms or unintended effects for the intervention, and discussion (trial limitations, 
generalizability, consideration of harms and benefits).  
Table 1 CENT 2015 checklist: CONSORT 2010 checklist items with modifications or additions for individual or series of N-of-1 trials [15] 
Section/topic Item no. CONSORT 2010 Item no. CENT 2015 
Title and abstract 
 
1a Identification as a randomized trial in the title 1a 
Identification as an “N-of-1 trial” in the title 
For series: identification as “a series of N-of-1 trials” in the title 
1b 
Structured summary of trial design, methods, results, and conclusions 




Background and objectives  
2a Scientific background and explanation of rationale 
  
2b Specific objectives or hypotheses 
  
  
2c Rationale for using N-of-1 approach 
Methods 
Trial design 3a 
Description of trial design (such as parallel, factorial) including 
allocation ratio 
3a 
Describe trial design, planned number of periods, and duration of each 
period (including run-in and wash out, if applicable)  
In addition for series: whether and how the design was individualized 
to each participant and explanation of the series design  
 
3b 
Important changes to methods after trial commencement 
(such as eligibility criteria), with reasons   
Participant(s) 
4a Eligibility criteria for participants 4a 
Diagnosis/disorder, diagnostic criteria, comorbid conditions, and 
concurrent therapies. 
For series: same as CONSORT item 4a 
4b Settings and locations where the data were collected 
  
   
4c 
Whether the trial(s) represents a research study and if so, whether 
institutional ethics approval was sought 
Interventions 5 
The interventions for each group with sufficient details to allow 
replication, including how and when they were actually administered  
5 
The interventions for each period with sufficient details to allow 
replication, including how and when they were actually administered  
Outcomes 6a 
Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed 
6a.1 
Description and measurement properties (validity and reliability) of 
outcome assessment tools 
 
6b Any changes to trial outcomes after the trial commenced, with reasons 
  
Sample size 
7a How sample size was determined 
  
7b 
When applicable, explanation of any interim analyses and stopping 
guidelines   
Randomization 
    
Sequence generation 
8a Method used to generate the random allocation sequence 8a 
Whether the order of treatment periods was randomized, with 
rationale, and method used to generate allocation sequence 
8b 
Type of randomization; details of any restriction (such as blocking and 
block size) 
8b 
When applicable, type of randomization; details of any restrictions 
(e.g., pairs, blocking) 
   




Mechanism used to implement the random allocation sequence (such as 
sequentially numbered containers), describing any steps taken to conceal 
the sequence until interventions were assigned 
  
Implementation 10 
Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions   
Blinding 
11a 
If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how   




Statistical methods used to compare groups for primary and secondary 
outcomes 
12a 
Methods used to summarize data and compare interventions for 
primary and secondary outcomes 
12b 
Methods for additional analyses, such as subgroup analyses and adjusted 
analyses 
12b 
For series: if done, methods of quantitative synthesis of individual trial 
data, including subgroup analyses, adjusted analyses, and how 
heterogeneity between participants was assessed, (for specific 
guidance on reporting syntheses of multiple trials, please consult the 
PRISMA Statement) 
   
12c 
Statistical methods used to account for carry-over effect, period 
effects, and intra-subject correlation 
Results 
Participant flow (a diagram is 
strongly recommended) 
13a 
For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analyzed for the primary 
outcome 
13a.1 
Number and sequence of periods completed and any changes from 
original plan with reasons 
13a.2 
For series: the number of participants who were enrolled, assigned to 
interventions, and analyzed for the primary outcome 
 
13b 
For each group, losses and exclusions after randomization, together with 
reasons 
13c 
For series: losses or exclusion of participants after treatment 
assignment, with reasons, and period in which this occurred, if 
applicable 
Recruitment 
14a Dates defining the periods of recruitment and follow-up 
  
14b Why the trial ended or was stopped 14b 
Whether any periods were stopped early and/or whether trial was 
stopped early, with reason(s) 
Baseline data 15 
A table showing baseline demographic and clinical characteristics for 
each group   
Numbers analyzed 16 
For each group, number of participants (denominator) included in each 
analysis and whether the analysis was by original assigned groups 
16 
For each intervention, number of periods analyzed 
In addition for series: if quantitative synthesis was performed, number 
of trials for which data were synthesized 
Outcomes and estimation 17a 
For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95 % confidence interval)  
17a.1 
For each primary and secondary outcome, results for each period; an 
accompanying figure displaying the trial data is recommended  
17a.2 
For each primary and secondary outcome, the estimated effect size and 
its precision (e.g., 95 % confidence interval)  
In addition for series: if quantitative synthesis was performed, group 
estimates of effect and precision for each primary and secondary 
outcome 
17b 
For binary outcomes, presentation of both absolute and relative effect 
sizes is recommended   
Ancillary analyses 18 
Results of any other analyses performed, including subgroup analyses 
and adjusted analyses, distinguishing pre-specified from exploratory 
18 
Results of any other analyses performed, including assessment of 
carry-over effects, period effects, intra-subject correlation 
In addition for series: if done, results of subgroup or sensitivity 
analyses 
Harms 19 
All important harms or unintended effects in each group (for specific 
guidance see CONSORT for harms) 
19 
All harms or unintended effects for each intervention (for specific 
guidance see CONSORT for harms) 
Discussion 
Limitations 20 
Trial limitations, addressing sources of potential bias, imprecision, and if 
relevant, multiplicity of analyses   
Generalizability 21 Generalizability (external validity, applicability) of the trial findings  
  
Interpretation 22 
Interpretation consistent with results, balancing benefits and harms, and 
considering other relevant evidence   
Other information 
Registration 23 Registration number and name of trial registry 
  
Protocol 24 Where the full trial protocol can be accessed, if available 
  
Funding 25 
Sources of funding and other support (such as supply of drugs), role of 
funders   
Extraction of study endpoints 
Type of study endpoint (e.g., self- report rating scale, objectively observed behaviors) will be 
recorded by two independent reviewers (JAS, LF). Extraction data for 20 % of studies will be 
compared between reviewers to ensure accuracy of data extraction. Review of these 
outcomes is intended to provide clinicians and researchers with information that may be of 
use as they design their own N-of-1 trials by allowing them to identify clinical conditions and 
outcomes that may be particularly amenable to N-of-1 methodology. 
Discussion 
This systematic review aims to add to the extant literature by reviewing data concerning N-
of-1 randomized trials with psychological and health behavior outcomes. Our review 
considers a wide variety of interventions and psychological and health behavior outcomes 
including, but not limited to, complementary and alternative medicine interventions, 
psychopharmacologic interventions, surgical interventions, behavioral interventions, and 
psychotherapeutic interventions. The findings will need to be considered alongside the 
plethora of other single-case designs that have dominated the fields of psychology and 
medicine to ensure their uniqueness. The findings might therefore serve as a springboard 
from which other N-of-1 trials could be developed and may minimize the tendency for 
researchers to miss reporting critical information required to understand the body of evidence 
available on any one topic. 
There are several limitations that will contextualize the findings and generalizability of the 
proposed review including our a priori decision to not quantitatively aggregate results. We 
made this decision as we expect disparate outcomes, time periods, and types of interventions 
across all behavioral and psychological domains. Moreover, we have chosen to exclude 
reports that contain insufficient trial detail, which limits the scope of this review. This 
limitation is important as many N-of-1 trials are embedded within larger editorial, review, 
and other articles, and their exact methodology is likely not ascertainable. Finally, N-of-1 
trials themselves may be limited due to the limited resources available to most practitioners. 
Nonetheless, their advantages over open trials of treatment are obvious, and services to 
conduct single-patient trials are becoming more available [16].  
In conclusion, although parallel-arm, between-person RCTs are the sine qua non of causal 
inference, there exist additional randomized designs that are useful in certain circumsta nces, 
such as when HTE is large and when the symptoms or outcomes can be measured within-
person, and the treatment is reversible. N-of-1 trials offer a low-cost means under these 
circumstances by which to overcome HTE, particularly by allowing for individualization of 
treatment. Although a previous systematic review has examined N-of-1 trials in the medical 
literature [1], a review of their use for interventions with psychological and health behavior 
outcomes in particular is lacking. The proposed review will thus help summarize the 
available evidence qualitatively and may guide the development of new N-of-1 trials. 
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